STAAR Surgical - STAA Stock Forecast, Price & News

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Price Performance

STAAR Surgical stock opened at $111.58 on Monday. The firm has a 50 day simple moving average of $75.73 and a 200-day simple moving average of $70.75. The stock has a market capitalization of $5.33 billion, a PE ratio of 166.54 and a beta of 1.09. STAAR Surgical has a 12-month low of $49.03 and a 12-month high of $163.08.

STAAR Surgical (NASDAQ:STAA - Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The medical instruments supplier reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.02. The business had revenue of $81.10 million during the quarter, compared to analysts' expectations of $80.12 million. STAAR Surgical had a net margin of 12.84% and a return on equity of 13.99%. The business's revenue was up 30.0% on a year-over-year basis. During the same period last year, the firm posted $0.19 earnings per share. On average, analysts forecast that STAAR Surgical will post 0.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

STAA has been the topic of several research reports. Canaccord Genuity Group increased their price objective on shares of STAAR Surgical from $89.00 to $97.00 in a research note on Thursday. BTIG Research upped their target price on shares of STAAR Surgical from $98.00 to $103.00 in a research report on Thursday. Canaccord Genuity Group upped their target price on shares of STAAR Surgical from $81.00 to $89.00 and gave the stock a "buy" rating in a research report on Tuesday, April 26th. Benchmark upped their target price on shares of STAAR Surgical from $97.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Needham & Company LLC upped their target price on shares of STAAR Surgical from $87.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $106.83.

Insider Activity

In other news, CEO Caren L. Mason sold 35,000 shares of the stock in a transaction that occurred on Thursday, May 19th. The shares were sold at an average price of $57.49, for a total value of $2,012,150.00. Following the completion of the transaction, the chief executive officer now directly owns 83,645 shares in the company, valued at $4,808,751.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.60% of the company's stock.